Advertisement

Hypertension pp 459-486 | Cite as

Biomedical Informatics Methods in Pharmacogenomics

  • Qing Yan
Part of the Methods In Molecular Medicine™ book series (MIMM, volume 108)

Abstract

Pharmacogenomics is the study of the genetic basis of individual variation in response to therapeutic agents. Pharmacogenomics may potentially affect on every step of health care and every drug treatment protocol. The optimal approach to pharmacogenomics in hypertension requires the integration of different disciplines, in which biomedical informatics plays an essential role. This chapter describes biomedical informatics methods used in dealing with key issues in pharmacogenomics. These key issues include the association between structure and function, the interaction between gene and drug, and the correlation between genotype and phenotype. Heterogeneous resources, including web sites, databases, and software analysis tools, are selected, organized, and integrated in practical methods to support these studies. Bioinformatics methods described in this chapter include genetic sequence searching, comparison, structural modeling, functional analysis, and systems biology studies, with emphasis on single-nucleotide polymorphism (SNP) analysis. Medical informatics methods such as disease and drug information and clinical terminology are also embraced in this chapter. This combination of both biological and medical informatics provides comprehensive methodologies to resolve complex problems in pharmacogenomics.

Key Words

Biomedical informatics bioinformatics pharmacogenomics single-nucleotide polymorphism (SNP) database software genotype phenotype structure function disease drug 

References

  1. 1.
    Yan, Q. (2003) Pharmacogenomics of membrane transporters: an overview, in: Membrane Transporters: Methods and Protocols (Yan, Q., ed.), Methods in Molecular Biology, Humana, Totowa, NJ, pp. 1–20.Google Scholar
  2. 2.
    Guidance for Industry Pharmacogenomic Data Submissions.US Department of Health and Human Services,Food and Drug Administration,http://www.fda.gov/cder/guidance/5900dft.pdf.Google Scholar
  3. 3.
    Mukherjee, D. and Topol, E.J. (2003) Pharmacogenomics in cardiovascular diseases. Curr. Probl. Cardiol. 28, 317–347.PubMedCrossRefGoogle Scholar
  4. 4.
    Siest, G., Ferrari, L., Accaoui, M. J., Batt, A. M., and Visvikis, S. (2003) Pharmacogenomics of drugs affecting the cardiovascular system. Clin. Chem. Lab. Med. 41, 590–599.PubMedCrossRefGoogle Scholar
  5. 5.
    Anderson, J. L., Carlquist, J. F., Horne, B. D., and Muhlestein, J. B. (2003) Cardiovascular pharmacogenomics: current status, future prospects. J. Cardiovasc. Pharmacol. Ther. 8, 71–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Rogers, K. L., Lea, R.A., and Griffiths, L. R. (2003) Molecular mechanisms of migraine: prospects for pharmacogenomics. Am. J. Pharmacogenomics 3, 329–343.PubMedCrossRefGoogle Scholar
  7. 7.
    Tafti, M. and Dauvilliers, Y. (2003) Pharmacogenomics in the treatment of narcolepsy. Pharmacogenomics 4, 23–33.PubMedCrossRefGoogle Scholar
  8. 8.
    McLeod, H. L. and Yu, J. (2003) Cancer pharmacogenomics: SNPs, chips, and the individual patient. Cancer Invest. 21, 630–640.PubMedCrossRefGoogle Scholar
  9. 9.
    Lenz, H.J. (2003) Pharmacogenomics in colorectal cancer. Semin. Oncol. 30, 47–53.PubMedCrossRefGoogle Scholar
  10. 10.
    Toffoli, G. and Cecchin, E. (2003) Pharmacogenetics of stomach cancer. Suppl. Tumori. 2, S19–S22.PubMedGoogle Scholar
  11. 11.
    Flores, C. M. and Mogil, J. S. (2001) The pharmacogenetics of analgesia: toward a genetically-based approach to pain management. Pharmacogenomics 2, 177–194.PubMedCrossRefGoogle Scholar
  12. 12.
    Hayney, M. S. (2002) Pharmacogenomics and infectious diseases: impact on drug response and applications to disease management. Am. J. Health Syst. Pharm. 59, 1626–1631.PubMedGoogle Scholar
  13. 13.
    Siffert, W. (2003) Cardiovascular pharmacogenetics: on the way toward individually tailored drug therapy. Kidney Int. Suppl. 84, S168–S171.PubMedCrossRefGoogle Scholar
  14. 14.
    Cadman, P. E. and O’Connor, D. T. (2003) Pharmacogenomics of hypertension. Curr. Opin. Nephrol. Hypertens. 12, 61–70.PubMedCrossRefGoogle Scholar
  15. 15.
    Bianchi, G., Staessen, J. A., and Patrizia, F. (2003) Pharmacogenomics of primary hypertension-the lessons from the past to look toward the future. Pharmacogenomics 4, 279–296.PubMedCrossRefGoogle Scholar
  16. 16.
    Tremblay, J., Hum, D. H., Sanchez, R., et al. (2003) TA repeat variation, Npr1 expression, and blood pressure: impact of the Ace locus. Hypertension 41, 16–24.PubMedCrossRefGoogle Scholar
  17. 17.
    Ranade, K., Wu, K. D., and Hwu, C. M., et al. (2001) Genetic variation in the human urea transporter-2 is associated with variation in blood pressure. Hum. Mol. Genet. 10, 2157–2164.PubMedCrossRefGoogle Scholar
  18. 18.
    Liljedahl, U., Karlsson, J., Melhus, H., et al. (2003) A microarray minisequencing system for pharmacogenetic profiling of antihypertensive drug response. Pharmacogenetics 13, 7–17.PubMedCrossRefGoogle Scholar
  19. 19.
    Yan, Q. (2003) Bioinformatics and data integration in membrane transporter studies. In Membrane Transporters: Methods and Protocols (Yan, Q., ed.), Methods in Molecular Biology, Humana, Totowa, NJ, pp.37–60.Google Scholar
  20. 20.
    Kitano, H. (2002) Systems biology: a brief overview. Science 295, 1662–1664.PubMedCrossRefGoogle Scholar
  21. 21.
    Jain, K. K. (2000) Applications of biochip and microarray systems in pharmacogenomics. Pharmacogenomics 1, 289–307.PubMedCrossRefGoogle Scholar
  22. 22.
    Hu, D. (2003) Microarray data analysis in studies of membrane transporters. In Membrane Transporters: Methods and Protocols (Yan, Q., ed.), Methods in Molecular Biology, Humana, Totowa, NJ, pp. 71–84.Google Scholar

Copyright information

© Humana Press Inc. 2005

Authors and Affiliations

  • Qing Yan
    • 1
  1. 1.MedImmune Inc.Mountain View

Personalised recommendations